LCZ696 Could Set New 'Gold Standard' for Heart Failure Treatment
With heart failure increasing in prevalence as the US population ages, early detection and more effective treatments are important. Now, data from clinical studies show that treatment with the experimental angiotensin receptor neprilysin inhibitor LCZ696 can significantly reduce patients' risk of sudden death and hospitalization.
With heart failure increasing in prevalence as the US population ages, early detection and more effective treatments are important. Now, data from clinical studies show that treatment with the experimental angiotensin receptor neprilysin inhibitor LCZ696 can significantly reduce patients' risk of sudden death and hospitalization.
Scott Solomon, MD, discussed the progress made in studies involving LCZ696 during an interview at the 2014 American Heart Association Scientific Sessions in Chicago.
